Characterization of an intravenous lipopolysaccharide inflammation model in broiler chickens.
Intravenous administration of lipopolysaccharide (LPS) from Escherichia coli O127:B8 at a dose of 1,500,000 u/kg body weight evoked a hypothermic response followed by a fever phase in 5-week-old broiler chickens. The hypothermic phase coincided with a severe decrease in blood pressure. We assume that this decrease in blood pressure is, at least partly, responsible for the hypothermic phase of the body temperature curve. LPS administration also caused a decrease in circulating white blood cells. The heterophils were predominantly sequestered in the lungs. In LPS-treated chickens, far more apoptotic leukocytes were present in the circulation, compared with control chickens. The molecular players responsible for the LPS-induced inflammatory response could be TL1A, IL-1beta and IL-6, since a slight increase in their mRNA levels in white blood cells was already seen 1 h after LPS administration. In accordance with these observations, the levels of secreted IL-6 were maximal 3 h after LPS administration. These parameters characterize this LPS-induced inflammation model in broiler chickens.
De Boever
S
S
Department of Pharmacology, Toxicology and Biochemistry, Faculty of Veterinary Medicine, Salisburylaan 133, 9820 Merelbeke, Ghent University, Belgium. sandra.deboever@ugent.be
Croubels
S
S
Meyer
E
E
Sys
S
S
Beyaert
R
R
Ducatelle
R
R
De Backer
P
P
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002645:Chickens; D004195:Disease Models, Animal; D015870:Gene Expression; D007022:Hypotension / Q000139:chemically induced; D007035:Hypothermia / Q000139:chemically induced; D007249:Inflammation / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology*; D007275:Injections, Intravenous; D053583:Interleukin-1beta / Q000235:genetics / Q000378:metabolism; D015850:Interleukin-6 / Q000235:genetics / Q000378:metabolism; D007962:Leukocytes / Q000187:drug effects / Q000473:pathology; D008070:Lipopolysaccharides / Q000008:administration & dosage; D008168:Lung / Q000187:drug effects / Q000473:pathology; D053380:Tumor Necrosis Factor Ligand Superfamily Member 15 / Q000235:genetics / Q000378:metabolism
D053583:Interleukin-1beta; D015850:Interleukin-6; D008070:Lipopolysaccharides; D053380:Tumor Necrosis Factor Ligand Superfamily Member 15